CIK 0001501989
- Accelerated filer
CytomX Therapeutics, Inc.
Sign in to watch- Ticker
- CTMX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 273521219
- Phone
- +1 650-515-3185
- Business address
- 151 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO, CA, 94080
- 4 Open-market sale Director sold 25,082 shares at $10.60 ($265,869)
- 4 Open-market sale Director sold 25,082 shares at $10.60 ($265,869)
- 4 Open-market sale Director sold 51,343 shares at an average $10.34 ($530,811)
- 4 Open-market sale Director sold 51,343 shares at an average $10.34 ($530,811)
- 4 Open-market sale Director sold 13,253 shares at an average $10.09 ($133,735)
- 4 Open-market sale Director sold 13,253 shares at an average $10.09 ($133,735)
- 4 Open-market sale Director sold 8,687 shares at an average $10.10 ($87,777)
- 4 Open-market sale Director sold 8,687 shares at an average $10.10 ($87,777)
- 4 Exercise or conversion Chief Financial Officer acquired 2,000 shares (option exercise)
- 4 Other disposition Director disposed of 300,000 shares (other)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Exercise or conversion Chief Scientific Officer and acquired 8,917 shares (option exercise)
- 4 Conversion 10% owner acquired 8,670,351 shares (conversion)
- 4 Conversion Director acquired 4,884,755 shares (conversion)
- 4 Open-market buy Senior VP and General Counsel bought 3,000 shares at $12.00 ($36,000)
- 4 Open-market buy CSO, Head Res.&Non-Clin. Dev. bought 5,000 shares at $12.00 ($60,000)
Page 19 of 20 · 400 filings